Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Roche’s ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
Autoimmunity's next top models.
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.
Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: a multicentre retrospective study on 361 patients
Low testosterone is associated with disability in men with multiple sclerosis.
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.
The origin and application of experimental autoimmune encephalomyelitis.
Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
Teriflunomide for multiple sclerosis.
USPTO list of patent term extensions
Defining the clinical course of multiple sclerosis: The 2013 revisions.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Pages